Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- (no title)
- IMF launches Myeloma Action Month to raise global awareness this March
- Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis
- Annamycin shows encouraging early results in Phase 2/3 AML clinical trial
- (no title)
- Soluble B-Cell Maturation Antigen as a Prognostic Marker for Progression-Free Survival in Multiple Myeloma Treated with BCMA-Directed Therapies: A Systematic Review and Meta-Analysis
- Clearnote’s blood test uses AI to spot pancreatic cancer in high-risk groups
- (no title)
- (no title)
- Immuno-gene therapy for brain cancer tumors now on FDA fast track